- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Fr | Artiva BioTherapeutics GAAP EPS of -$0.63 | 1 | Seeking Alpha | ||
| 22.07. | Artiva Biotherapeutics, Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| 17.07. | Artiva Biotherapeutics, Inc.: Artiva Biotherapeutics Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | 1 | GlobeNewswire (USA) | ||
| 08.06. | Artiva presents rheumatoid arthritis therapy data at EULAR | 4 | Investing.com | ||
| 08.06. | Artiva Biotherapeutics, Inc.: Artiva Biotherapeutics Highlights AlloNK Data Presented at EULAR 2026, FDA RMAT Designation in Refractory Rheumatoid Arthritis and Webcast Today | 2 | GlobeNewswire (USA) | ||
| 26.05. | Cantor Fitzgerald reiterates Artiva Biotherapeutics stock rating | 2 | Investing.com | ||
| 26.05. | Cantor Fitzgerald bekräftigt "Overweight"-Rating für Artiva Biotherapeutics | 5 | Investing.com Deutsch | ||
| ARTIVA BIOTHERAPEUTICS Aktie jetzt für 0€ handeln | |||||
| 19.05. | Artiva to present AlloNK therapy data at EULAR congress | 1 | Investing.com | ||
| 19.05. | Artiva Biotherapeutics, Inc.: Artiva Biotherapeutics Announces Multiple AlloNK Data Presentations at EULAR 2026 Congress, Including Late-Breaking Oral Presentation Highlighting Clinical Efficacy Comparable to Autologous CAR T-Cell Therapy in ... | 5 | GlobeNewswire (USA) | ||
| 19.05. | Artiva Biotherapeutics appoints Diego Miralles as president, R&D head | 1 | Investing.com | ||
| 19.05. | Artiva Biotherapeutics beruft Diego Miralles zum President und Leiter für Forschung und Entwicklung | 1 | Investing.com Deutsch | ||
| 19.05. | Artiva Biotherapeutics, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 19.05. | Artiva Biotherapeutics, Inc.: Artiva Biotherapeutics Appoints Veteran Biotech Executive and Drug Developer Diego Miralles, M.D., as President and Head of Research and Development | 822 | GlobeNewswire (Europe) | Veteran biotechnology executive with more than 20 years of leadership experience spanning research, clinical development, commercialization and company building Proven track record advancing multiple... ► Artikel lesen | |
| 11.05. | H.C. Wainwright raises Artiva Biotherapeutics price target to $35 | 2 | Investing.com | ||
| 11.05. | GC Cell's Artiva Raises $300 Million for Phase 3 RA Trial | 2 | BusinessKorea | ||
| 08.05. | Artiva Biotherapeutics Stock Slides Despite Positive Trial Data | 3 | Benzinga.com | ||
| 08.05. | Artiva rises after mid-stage trial data for lead asset in rheumatoid arthritis | 1 | Seeking Alpha | ||
| 08.05. | Artiva BioTherapeutics GAAP EPS of -$0.95 | 1 | Seeking Alpha | ||
| 08.05. | Artiva Biotherapeutics Prices $300 Mln Stock, Pre-Funded Warrants Offering; Shares Rise | 1 | RTTNews | ||
| 08.05. | Artiva reports clinical trial data for rheumatoid arthritis therapy | 3 | Investing.com |
1 2 Weiter >>
35 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BIONTECH | 80,70 | +3,33 % | BioNTech SE und Emyria Limited: Wenn schlafende Biotech-Riesen erwachen und datenstarke Plattformen den Markt erobern | ||
| AMGEN | 355,85 | +0,13 % | Ihre wichtigsten Termine: Q2-Updates von SpaceX, Bayer, Biontech, Spotify, Pfizer, Continental, Merck & Co | © Foto: Dall-EGut geplant in den Tag. Mit dem wO-Tagesausblick haben Sie die wichtigsten Termine im Blick und starten bestens vorbereitet in den neuen Handelstag.Untermehmenstermine 05:00 Uhr, Großbritannien:... ► Artikel lesen | |
| NOVAVAX | 6,850 | -0,29 % | Novavax, Inc.: Novavax Reports Second Quarter 2026 Financial Results and Operational Highlights | Reported total revenue of $57 million for the second quarter of 2026 and raised full-year 2026 Revenue Framework
Improved GAAP Combined R&D and SG&A expense... ► Artikel lesen | |
| BIOGEN | 178,40 | -0,82 % | Biogen Inc.: Biogen Completes Acquisition of RayThera Inc. | Lead program now in Phase 1 developmentCAMBRIDGE, Mass., Aug. 06, 2026 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) today announced the completion of the acquisition of RayThera Inc., a privately... ► Artikel lesen | |
| BIOFRONTERA | 2,490 | -2,73 % | PTA-Adhoc: Biofrontera AG: Biofrontera AG beschließt Vorbereitung des Wechsels vom regulierten Markt (Prime Standard) in das Börsensegment Scale | DJ PTA-Adhoc: Biofrontera AG: Biofrontera AG beschließt Vorbereitung des Wechsels vom regulierten Markt (Prime Standard) in das Börsensegment Scale
Veröffentlichung von Insiderinformationen gemäß... ► Artikel lesen | |
| BIONXT SOLUTIONS | 0,207 | +5,08 % | Viking Therapeutics, BioNxt Solutions, Bausch Health - Studienerfolg entfacht neue Fantasie | Die Pharmaindustrie steht vor einer neuen Wachstumsphase. Milliarden fließen in innovative Therapien, moderne Arzneimitteltechnologien und die Weiterentwicklung etablierter Medikamente. Besonders dynamisch... ► Artikel lesen | |
| VIKING THERAPEUTICS | 29,250 | -1,35 % | Viking Therapeutics Declined in July, and why its Long-Term Prospects are Undiminished | ||
| INTELLIA THERAPEUTICS | 10,300 | -0,39 % | Intellia Therapeutics, Inc.: Intellia Therapeutics Announces Second Quarter 2026 Financial Results and Business Updates | Positive Phase 3 HAELO clinical data for lonvo-z in HAE presented at EAACI and published in New England Journal of MedicineAnticipate FDA acceptance of BLA for lonvo-z in second half of 2026 and U.S.... ► Artikel lesen | |
| TEMPUS AI | 45,180 | +0,30 % | BTIG cuts Tempus AI stock price target to $70 on model update | ||
| BIOCRYST PHARMACEUTICALS | 8,172 | +0,79 % | Biocryst outlines $690M-$715M 2026 total revenue guidance with operating costs at $420M-$440M | ||
| BIOMARIN PHARMACEUTICAL | 55,16 | +6,90 % | BioMarin Pharmaceutical Inc.: BioMarin Reports Second Quarter 2026 Financial and Operating Results | Second Quarter 2026 Total Revenues Increased 20% Year-over-year to $990 million
Stronger Growth Expectations Drive Increased Guidance for Full-year 2026 Total Revenues... ► Artikel lesen | |
| EXELIXIS | 46,000 | -1,67 % | Exelixis outlines zanza CRC launch plans as 2026 revenue guidance midpoint is lowered by $50M | ||
| SAREPTA THERAPEUTICS | 14,720 | +1,38 % | Sarepta's Q2 Earnings & Sales Beat Estimates, '26 Outlook Updated | ||
| PACIFIC BIOSCIENCES OF CALIFORNIA | 1,021 | -0,39 % | PacBio Announces Second Quarter 2026 Financial Results | MENLO PARK, Calif., Aug. 05, 2026 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB) today announced financial results for the quarter ended June 30, 2026. Recent Business Highlights Total revenue of $39.0... ► Artikel lesen | |
| CARDIOL THERAPEUTICS | 1,236 | +0,98 % | Stocks in Play: Cardiol Therapeutics Inc. |
ARTIVA BIOTHERAPEUTICS INC gehört der Branche Biotechnologie an. Mit einer aktuellen Kursveränderung von -0,025 (-0,22 %) liegt der Kurs bei 11,245 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu ARTIVA BIOTHERAPEUTICS INC finden Sie auf Wallstreet Online.